Small-molecule compounds inhibiting S-phase kinase-associated protein 2: a review
J Jing, L Rui, S Junyuan, Y Jinfeng, H Zhihao… - Frontiers in …, 2023 - frontiersin.org
S-phase kinase-associated protein 2 (Skp2) is a substrate-specific adaptor in Skp1-CUL1-
ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 …
ROC1-F-box E3 ubiquitin ligases and widely regarded as an oncogene. Therefore, Skp2 …
[HTML][HTML] Advances in Understanding and Management of Erdheim-Chester Disease
AM Kulkarni, PKR Gayam, JM Aranjani - Life Sciences, 2024 - Elsevier
Abstract Erdheim Chester Disease (ECD) is a rare histiocytic disorder marked by infiltration
of organs with CD68+ histiocytes. ECD stems from mutations of BRAF and MAP2K1 in …
of organs with CD68+ histiocytes. ECD stems from mutations of BRAF and MAP2K1 in …
Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
J Peng, Z Lin, W Chen, J Ruan, F Deng, L Yao, M Rao… - Heliyon, 2023 - cell.com
More than one half melanoma patients have BRAF gene mutation. BRAF inhibitor
vemurafenib is an effective medication for these patients. However, acquired resistance is …
vemurafenib is an effective medication for these patients. However, acquired resistance is …
A method for measuring serum levels of melanin-associated indole metabolites using LC-MS/MS and its application to malignant melanoma
M Takiwaki, H Umemura, Y Kikutani, S Fukuzawa… - Clinica Chimica …, 2024 - Elsevier
Background and aims With the development of novel therapies for advanced malignant
melanoma (MM), biomarkers that can accurately reflect the progression of MM are needed …
melanoma (MM), biomarkers that can accurately reflect the progression of MM are needed …
Long Term results and prognostic biomarkers for Anti-PD1 immunotherapy used after BRAFi/MEKi combination in Advanced Cutaneous Melanoma Patients
P Rogala, AM Czarnecka, B Cybulska-Stopa… - Cancers, 2022 - mdpi.com
Simple Summary Second line anti-PD1 immunotherapy is effective in selected BRAF-
mutated melanoma patients after BRAFi/MEKi immunotherapy failure. Nivolumab and …
mutated melanoma patients after BRAFi/MEKi immunotherapy failure. Nivolumab and …
Protein–Protein Interactions in Cancer
Cancerous state is often associated with the aberrant expression of several critical proteins,
which in turn, modulate interactions with other proteins. Therefore, researchers have tried to …
which in turn, modulate interactions with other proteins. Therefore, researchers have tried to …
Application of Rapidly Accelerating Fibrosarcoma Protein Degraders in Drug Discovery
RB Kargbo - ACS Medicinal Chemistry Letters, 2022 - ACS Publications
BRAF (B-Raf proto-oncogene or v-Raf murine sarcoma viral oncogene homolog B) is a
human gene that encodes B-Raf serine/threonine protein kinase. BRAF plays a critical role …
human gene that encodes B-Raf serine/threonine protein kinase. BRAF plays a critical role …
[PDF][PDF] Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients …
P Rogala, AM Czarnecka, B Cybulska-Stopa… - 2022 - academia.edu
(1) Background: BRAFi/MEKi are usually offered as a first line treatment for patients
requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor …
requiring rapid response; with elevated lactate dehydrogenase (LDH) activity, large tumor …